Lilly advertises Zepbound self-pay at $299 a month. That price is real, and on a standard titration it covers your first four weeks. The Zepbound cost you actually live with is set by your dose, and the self-pay ladder climbs to $449 once you pass 5 mg. Standard titration walks most patients into the top rung within a few months.

What you pay depends on which of five routes you qualify for, and the gap between the best and worst of them is wider than most people expect.

How Much Does Zepbound Cost? The Short Answer

There are five real ways to pay for Zepbound in 2026. Which one you get is decided almost entirely by your insurance status, not by shopping around.

RouteWhat you payWhat it requires
LillyDirect self-pay$299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 mg and aboveNo insurance needed. Ordered through LillyDirect. Taxes and fees on top.
Commercial insurance that covers ZepboundAs little as $25 for up to a 3-month prescriptionSavings card, plus an approved prior authorization. Capped at $1,300 a year.
Commercial insurance that does not cover the KwikPen$299 per monthSavings card. Same as the bottom self-pay rung.
Medicare Part DNo more than $50 per monthGLP-1 Bridge, KwikPen only, through 31 December 2027.
Medicaid$0 to a nominal copayOne of the 13 states covering obesity GLP-1s as of January 2026.

The brand price is set by milligrams, so your bill rises as your dose rises. And the routes are not close together. A $449 self-pay month is nine times a $50 Bridge month and eighteen times a $25 card month, which means route selection matters far more than any discount you can negotiate.

The rest of this page works through each route, the fine print that changes the number, and how brand self-pay now compares to compounded tirzepatide. For pricing across the whole drug class, see our GLP-1 cost guide. For everything else about the medication, start at our Zepbound hub.

Zepbound Self-Pay Pricing Through LillyDirect, Dose by Dose

Self-pay is the unusual part of Zepbound’s pricing, and it deserves more attention than it gets. Lilly publishes a cash price that requires no insurance at all. You do not need a plan, a card, or an approved prior authorization to reach it.

What the self-pay ladder costs at each strength

DoseSelf-pay price per monthAnnual cost at 11 self-pay fills
2.5 mg$299$3,289
5 mg$399$4,389
7.5 mg$449$4,939
10 mg$449$4,939
12.5 mg$449$4,939
15 mg$449$4,939

The ladder flattens at 7.5 mg. Going from 7.5 mg to 15 mg costs nothing extra, which is worth knowing if you are worried that every increase brings another bill.

The Zepbound KwikPen launched on 23 February 2026 and is sold through LillyDirect on a self-pay basis. The self-pay ladder is not pen-exclusive, so do not assume a vial prescription disqualifies you. Confirm the presentation against the price when you order, because the Medicare route further down this page is genuinely KwikPen only.

The two limits printed in the footnotes

Lilly caps the self-pay card at 11 prescription fills per calendar year. A strict 28-day refill cadence needs 13 fills to cover 12 months. Two of your months therefore fall outside the self-pay price, which nobody mentions when quoting an annual total.

Watch this number carefully, because Lilly runs two different fill caps. The self-pay card allows 11 fills a year. The commercial savings card, covered further down, allows 13. They are separate programs and you cannot mix them, so if you are self-paying, budget on 11.

The second limit is shorter to state. Lilly’s own terms say additional taxes and fees may apply, so $299 is the medication price rather than the checkout total.

Neither limit makes self-pay a bad route. For someone with no coverage it is the cheapest legitimate brand access that exists, and it is the reason our guide to GLP-1s without insurance treats Zepbound differently from the rest of the class. If you have not started yet, our page on how to get Zepbound covers the prescription side.

The Dose Escalation Trap: A 50% Price Climb Built Into the Label

$299 to $449 is a 50% increase. What makes Zepbound worth studying is that the drug’s own titration schedule walks you up that ladder, on a timetable set by the prescribing label rather than by anything you choose.

Dosing starts at 2.5 mg for four weeks. Most patients move to 5 mg next, and 7.5 mg is a common step after that. Follow the standard path and you can be paying the top price by month three.

Here is what that does to a year. A patient who titrates normally pays $299, then $399, then $449 for the remaining nine fills. That comes to $4,739. Someone who stays at 2.5 mg for all 11 self-pay fills pays $3,289. The same drug, the same year, $1,450 apart.

The increase is a pricing decision, not a clinical one. More milligrams cost more here because Lilly prices by strength. That is a choice, and it is not the only way to do it. Several compounded providers price by the month instead, so the number on the invoice does not move when the dose does.

Carry two things forward from this. Compare Zepbound to anything else at your maintenance dose, not your starting dose. And if a lower dose holds your results, the saving is unusually large on this particular ladder, which is part of why microdosing gets discussed as a cost strategy rather than only a tolerance one.

Our tirzepatide cost page runs the same arithmetic across every product built on this molecule.

Zepbound Cost With Commercial Insurance

The $25 figure in Lilly’s marketing is real. It is also capped in three directions, and the caps decide your year more than the headline does.

The savings card, and what it caps

With commercial insurance that covers Zepbound, the Zepbound Savings Program starts at $25 for up to a 3-month prescription. Then the limits arrive. This card allows 13 fills per calendar year, not the 11 the self-pay card allows, and it expires on 31 December 2026.

The caps are where the headline gets cut down. The card contributes at most $100 toward a 1-month fill, $200 toward a 2-month fill, and $300 toward a 3-month fill, with total savings capped at $1,300 for the calendar year. You reach $25 only when the card’s contribution covers most of what your plan left you owing. If your plan hands you coinsurance well above $125 on a 1-month fill, the card takes $100 off that and you pay the rest. Patients with thin coverage often exhaust the $1,300 before December and finish the year paying their full cost share.

Your deductible comes first

Covered does not mean cheap in January. If your plan carries a $3,000 pharmacy deductible, you pay the negotiated price yourself until that deductible is met, and the copay you were quoted only starts after it.

This catches people every year. A patient with good coverage can pay several hundred dollars a month through the first quarter, hit the deductible in spring, and spend the rest of the year at $25. The annual total is what to compare, not the copay printed on your card.

Ask your plan for two numbers before you budget: your pharmacy deductible, and which formulary tier Zepbound sits on. A high tier with coinsurance rather than a flat copay can leave you paying a percentage of the full price all year.

If your plan does not cover the KwikPen

Lilly runs a second card tier for people whose commercial plan excludes the KwikPen. It brings the price to $299 per month.

Look at that number again. It is identical to the 2.5 mg self-pay price. At the bottom of the ladder the card delivers nothing that self-pay does not already give you, and self-pay does not require you to have insurance in the first place.

One exclusion matters more than any of the caps. Lilly’s terms state that governmental beneficiaries are excluded and that the card is not insurance. Medicare, Medicaid, VA and TRICARE patients cannot use it at all, whatever their plan covers. Our GLP-1 comparison guide sets out how the major products differ on coverage as well as effect.

Prior Authorization: Why Coverage Fails Half the Time

Prior authorization for GLP-1s is approved 48% of the time for weight loss. For the same drug prescribed for diabetes, it is approved 90% of the time (Pham et al., JMCP 2026).

Same molecule. Same paperwork. Roughly half the approval rate. The variable is the indication written on the form.

That gap is the reason “my insurance covers it” so often turns out to be wrong. A plan can list Zepbound on its formulary and still deny your specific request, because formulary placement and prior authorization are separate decisions made by separate processes.

The cost consequence is concrete. A denial converts a $25 month into a $299 to $449 month, and appeals commonly take several weeks. Budget for the gap rather than assuming it away, because a first-pass denial is close to a coin flip.

Denials usually cite one of three things: a BMI threshold you have not documented, a comorbidity requirement, or step therapy that wants you to fail a cheaper drug first. All three are answerable with records your prescriber already holds, which is why filing the appeal is usually worth the effort at a 48% baseline.

Two escalation routes exist beyond the standard appeal, and both are underused. A peer-to-peer review puts your prescriber on the phone with the plan’s reviewing clinician, which resolves documentation disputes faster than another round of forms. If the internal appeal fails, most commercial plans then offer an external review by a reviewer outside the plan. Whether you are entitled to one, who runs it, and whether the outcome binds the plan all depend on your plan type and your state, so ask your plan for its external review process in writing.

While any of this is running, you are paying. That is the practical reason to know the self-pay ladder even if you expect coverage: it is your fallback price during the weeks the paperwork takes, and a $299 fallback changes how long you can afford to keep appealing. Our page on how to get Zepbound covers the documentation side.

Zepbound Cost on Medicare and the GLP-1 Bridge

Medicare patients have spent years being told that weight-loss drugs are simply not covered. For the next 18 months that is no longer true, and the price is $50 a month.

The Medicare GLP-1 Bridge runs from 1 July 2026 to 31 December 2027. Eligible Part D patients with a Zepbound prescription for weight management pay no more than $50 per month. Lilly is explicit that this is not a guarantee of coverage and that eligibility runs on the Bridge clinical criteria.

Three details change how you should plan around it.

  • It ends on 31 December 2027. The Bridge is a time-limited program, not a permanent price. Anyone building a multi-year budget should assume the number changes at that point.
  • KwikPen only. A vial prescription does not qualify. If your prescriber writes vials out of habit, the Bridge price does not apply.
  • Bridge spending is excluded from the $2,100 Part D out-of-pocket cap. This is the catch worth understanding. Money you pay through the Bridge does not count toward the cap, so it does not move you closer to catastrophic coverage on your other medications.

That last point cuts both ways. $50 a month is a genuinely low price, and it is also $600 a year of spending that buys you no progress toward the cap. For a Part D patient with several expensive prescriptions, the arithmetic is worth running before assuming the Bridge is strictly better.

Medicare patients should also note what they cannot use. The commercial savings card excludes governmental beneficiaries, so the $25 tier is closed to you regardless of your Part D plan.

Zepbound and Medicaid: What Changed on 1 January 2026

Medicaid obesity coverage is contracting. Thirteen states covered obesity GLP-1s as of January 2026. Four states dropped that coverage on 1 January 2026: California, Pennsylvania, New Hampshire and South Carolina.

If you live in one of those four and last checked in 2025, your answer has changed. We are not doing the subtraction between those two figures, because what we can verify does not settle whether the count of 13 is measured before or after the January withdrawals.

The split that survives is the same indication asymmetry driving prior authorization denials. Medicaid coverage for type 2 diabetes is close to universal. Coverage for obesity is optional, which makes it a line item that moves whenever a state budget tightens.

Check your state’s current preferred drug list before you plan around Medicaid, and check it again at the start of each state fiscal year. We are not printing a state-by-state table, because a list that goes stale between budget cycles is worse than no list. Your state’s own formulary is the only current answer.

Zepbound Versus Mounjaro on Cost

Zepbound and Mounjaro are the same molecule from the same manufacturer. Their cash-access rules have almost nothing in common, and that asymmetry is probably the most useful thing on this page.

Cost factorZepboundMounjaro
Approved indicationObesity and obstructive sleep apneaType 2 diabetes
Published self-pay price ladderYes. $299 to $449 by doseNone
Savings card where the plan covers itFrom $25 for up to a 3-month prescription. $1,300 annual cap$25 per fill
Cash route where the plan does not cover it$299 per monthAs low as $499 per month
Reachable with no insurance at allYesNo

The bottom row is the one that matters. Mounjaro’s $499 tier is delivered through a savings card, and that card requires commercial insurance while excluding governmental beneficiaries. Someone with no insurance cannot reach $499. The same person can reach $299 on Zepbound self-pay today.

On the non-covered tier itself, Mounjaro’s card is the more generous instrument. It absorbs up to $647 in a month and up to $8,411 across a year, which is far more assistance than Zepbound’s card provides on its own non-covered tier. All of it is reserved for people who already hold commercial insurance.

So the common advice to ask for Mounjaro instead to save money runs backwards for self-pay patients. It can make sense for someone with commercial coverage and a diabetes diagnosis. It makes no sense as a cost strategy for an uninsured person seeking weight management, and the indication on the prescription is a clinical question for your prescriber rather than a pricing lever.

Our tirzepatide hub covers how the two brands relate on dosing and supply as well as price.

How Zepbound Self-Pay Compares to Wegovy and Ozempic

Novo Nordisk sells self-pay semaglutide through NovoCare, and it prices it on a completely different logic. Wegovy is flat. Zepbound is a ladder. That single structural difference decides which brand is cheaper for you, and it flips partway up the dose range.

ProductSelf-pay priceHow it is structured
Zepbound (tirzepatide)$299, $399, then $449Priced by strength. Climbs with your dose, flat from 7.5 mg up.
Wegovy (semaglutide)$349One price for all doses from 0.25 through 2.4 mg. $199 for the first 2 fills at 0.25 or 0.5 mg for new patients, through 31 December 2026.
Wegovy HD (7.2 mg)$399The high-dose pen sits one step above the standard flat price.
Ozempic (semaglutide)$349, or $499 at 2 mgDiabetes-indicated. $349 at 0.25, 0.5 and 1 mg. The $499 tier applies to 2 mg only.
Wegovy tablets$149 to $299$149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg.

Read the first two rows together and the crossover is obvious. At a starting dose Zepbound is the cheaper injection, $299 against $349. At any maintenance dose from 7.5 mg upward, Wegovy is cheaper, $349 against $449. The gap at maintenance is $100 a month, or about $1,100 across 11 self-pay fills.

Watch for three traps, all of which appear in cost articles that should know better.

  • The $499 figure belongs to Ozempic at 2 mg only. It does not exist for Wegovy at any dose. Wegovy self-pay came down to $349 on 17 November 2025.
  • Wegovy’s $199 is an introductory price, not a monthly rate. It covers 2 fills, at 0.25 or 0.5 mg, for new patients, and it expires on 31 December 2026. Comparing it to Zepbound’s $299 compares an intro offer to an ongoing price.
  • The packages are not the same size. A Wegovy month is one box of four pens. An Ozempic month is one box of one pen. Per-month prices are comparable; per-pen prices are not.

A fourth point of confusion sits on the oral side. There are now three oral semaglutide products, and their dose ladders overlap without matching. Oral Wegovy comes in 1.5, 4, 9 and 25 mg. The 3, 7 and 14 mg strengths belong to Rybelsus, which has no self-pay program at all, only a $25 card for commercially insured patients who already have coverage.

None of this makes one molecule the right answer. Tirzepatide and semaglutide differ on effect size and side effect profile, and that comparison belongs with your prescriber. On price alone, the rule is short: Zepbound wins at the bottom of the ladder and loses at the top. Our semaglutide cost page works through the NovoCare side in full.

What Zepbound’s List Price Is, and Why We Are Not Printing One

Cost articles love a list price. It is a big round-sounding number that makes every other figure look like a bargain, and it is also the number almost nobody pays.

The mechanism is worth understanding even without a figure. List price, or wholesale acquisition cost, is what a wholesaler pays the manufacturer. It is not what a pharmacy charges and it is not what a plan pays. Rebates negotiated with pharmacy benefit managers sit between list and net, and those rebates are confidential, which is precisely why the gap between the two is so large and so hard to verify.

We could not verify a Zepbound list price against an authoritative source, so we are not printing one. The four-figure numbers that circulate in cost articles are quoted without attribution, and repeating them would only launder an unsourced figure into another page.

Lilly’s own paperwork shows why the number is so hard to pin down. The savings-card benefit is defined as wholesale acquisition cost minus $499. Lilly prices the discount against WAC without publishing WAC, so the figure governs what patients pay while staying out of public view.

That absence matters less than it looks. A list price is not a number you can pay. It is not the pharmacy’s price, it is not your plan’s price, and it is not the self-pay price. Budget against the ladder and the card caps instead, because those are the figures that will appear on your statement.

Zepbound Self-Pay Versus Compounded Tirzepatide

The old story was that compounded tirzepatide costs half what the brand costs. That was true when the brand’s cheapest cash route was several hundred dollars higher. It is much less true in 2026.

Compounded tirzepatide is not an FDA-approved product. The FDA does not review compounded medications for safety, effectiveness, or manufacturing quality. Compounding is lawful under the 503A pathways described below, which is a separate question from approval.

At standard monthly rates, compounded tirzepatide from the telehealth providers we track runs roughly $199 to $399. Eden lists $199 a month. Mochi Health lists $199 a month plus a required $79 monthly membership. ReflexMD is $297, Goby Meds and ShedRx are both $299, Peak Wellness is $279 for the first month and $349 after that with no membership fee, and TrimRx is $399. Several of these hold one price across every dose, which is the structural difference from a ladder rather than a discount.

Now set that against the brand ladder. Zepbound self-pay starts at $299. At 2.5 mg the brand sits inside the compounded range rather than above it. The gap opens at 5 mg, where $399 is above every compounded price here except TrimRx, and by $449 the brand is above all of them.

Which means the comparison depends entirely on your dose. At a starting dose, an FDA-approved product costs about what a compounded one does. At a maintenance dose, compounded is clearly cheaper. Across 11 self-pay fills the gap runs from about $550 against the most expensive compounded option to about $2,750 against the cheapest.

The legal footing has also moved, and it moves in one direction. 503B large-scale compounding has been restricted since March 2025 and faces permanent exclusion under the FDA’s proposed rule of 30 April 2026 (91 Fed. Reg. 23431). 503A patient-specific compounding remains lawful where there is documented individual medical need, such as an allergy to an inactive ingredient, a dose strength not commercially available, or a different delivery route. The frequently cited four-or-fewer-prescriptions-per-month position is FDA enforcement discretion rather than a statutory protection, and it reflects how the agency is expected to act rather than a rule you can rely on. OFA v. FDA remains unresolved: the district court upheld FDA on 7 May 2025, and the Fifth Circuit heard argument on 30 March 2026 without ruling.

This page prices routes and does not rank providers. If you want the ranking, that work lives on our cheapest tirzepatide page and our compounded tirzepatide page, both of which score providers on which pharmacy prepared the medication and whether they name it before you pay. Our guide to buying tirzepatide online covers the ordering process.

The Zepbound Costs Nobody Quotes You

The medication price is not the bill. Six things get added after the number you were quoted.

  • Taxes and fees. Lilly’s own footnote says additional taxes and fees may apply on the self-pay price.
  • The 11-fill self-pay cap. The self-pay card covers 11 fills a calendar year, while a 28-day cadence needs 13 to cover 12 months, so two months fall outside the self-pay price. Do not borrow the commercial card’s 13-fill allowance here. It is a different program.
  • Prescriber visits. Self-pay buys medication. The prescription behind it is a separate transaction with its own fee.
  • Baseline and monitoring labs. Not included in any manufacturer price, on any route.
  • Sharps disposal. Smaller with a pen than with vials and syringes, but still yours to arrange.
  • The prior authorization gap. At a 48% approval rate, plenty of people self-pay for a month or three while appealing.

One of these is worth its own paragraph, because it is the only one you fully control.

Self-pay refills must be completed within 45 days of the delivery date of your previous prescription. Miss that window and you lose the program price. It is a quiet trap, because a delayed prescriber response, a holiday, or two weeks of feeling too nauseated to think about logistics can all push you past day 45. Set a reminder for day 30 rather than day 45, and treat the refill as something to start early rather than something to do when the pen runs out.

What Happens to Your Cost If You Stop Zepbound

Every price on this page is a subscription price, and the trial data explains why.

SURMOUNT-4 measured what happens after tirzepatide stops. After 36 weeks of treatment, patients switched to placebo regained a mean of 14% of body weight over the following 52 weeks. A post hoc analysis of the same trial found that 254 of 308 patients, or 82.5%, regained at least a quarter of the weight they had lost within roughly a year.

Whether to continue is a decision for you and your prescriber, and it turns on more than money. What the data settles is the budgeting question. Pricing Zepbound as a finite course of treatment does not match how the drug behaves, so compare annual totals rather than first-month promotions when you are choosing a route.

It is also the assumption sitting underneath every cost-effectiveness model, which is where the numbers stop agreeing. Our page on how long you should take GLP-1 drugs goes through the duration question in detail.

Is Zepbound Worth the Money? Two Answers That Disagree

Two published analyses priced this class seven months apart in the same year and landed 3.4 times apart.

ICER, in October 2025, put semaglutide at $57,779 per quality-adjusted life year and concluded that no discount from the current price was needed. JAMA Health Forum, in March 2025, put the same drug at $197,023 per QALY and concluded it needed a 30.5% price cut to be cost-effective.

Both figures are for semaglutide. We are reporting them as the class benchmark rather than as Zepbound numbers, because transferring a semaglutide QALY figure to tirzepatide without saying so would be exactly the kind of quiet substitution that makes cost writing untrustworthy.

The models diverge on two assumptions: how long patients stay on treatment, and whether the modeled price is list or net after rebates. Change either and the answer moves by more than a factor of three.

That is genuinely unsettled, and we are not going to pretend otherwise. It does leave you something usable, though. The two variables driving the disagreement, duration and net price, are both things you can estimate for your own case. Your route determines your net price. Your intentions and your prescriber determine your duration.

The Cheapest Legitimate Zepbound Route for Your Situation

Collapse everything above into your own circumstances and it comes down to five cases.

  • Commercial insurance that covers Zepbound. Use the savings card, from $25 for up to a 3-month prescription. Watch the $1,300 annual cap, and expect to pay more once you exhaust it.
  • Commercial insurance that denied your prior authorization. Appeal, and self-pay while you wait. At a 48% first-pass approval rate, a denial says little about the strength of your case.
  • No insurance at all. LillyDirect self-pay at $299 to $449 by dose is the cheapest brand access available. Protect the 45-day refill window, because that is the mistake that costs the most.
  • Medicare Part D. The GLP-1 Bridge at no more than $50 a month through 31 December 2027, KwikPen only. Remember it does not count toward the $2,100 out-of-pocket cap.
  • Medicaid. Check your state’s current list. Four states dropped obesity coverage on 1 January 2026, so a 2025 answer is not reliable.

If you are weighing compounded tirzepatide, the honest summary is that the ranges now overlap at low doses and separate at maintenance doses. The provider ranking is on our cheapest tirzepatide page rather than here. And if you are still deciding between molecules, our semaglutide cost page runs the same analysis on the other side of the class.

Zepbound Cost FAQ

How much does Zepbound cost per month?

On LillyDirect self-pay it is $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above, plus taxes and fees. With commercial insurance that covers Zepbound, the savings card starts at $25 for up to a 3-month prescription. Eligible Medicare Part D patients pay no more than $50 a month through the GLP-1 Bridge.

How much does Zepbound cost without insurance?

$299 to $449 a month depending on your dose, through LillyDirect self-pay, plus taxes and fees. No insurance is needed to get that price, which makes Zepbound unusual in this class. The self-pay card is capped at 11 fills per calendar year, not the 13 the commercial savings card allows, and refills must be completed within 45 days of your previous delivery date.

Why did my Zepbound price go up when my dose went up?

The self-pay program prices by strength rather than by month. You pay $299 at 2.5 mg, $399 at 5 mg, and $449 from 7.5 mg upward, so standard titration walks you up the ladder. The ladder flattens at 7.5 mg, so increases beyond that point cost nothing extra. See The Dose Escalation Trap above for the annual arithmetic.

Is Mounjaro cheaper than Zepbound?

Not for a self-pay patient. Zepbound has a published self-pay ladder of $299 to $449 that anyone can use, including people with no insurance. Mounjaro has no equivalent ladder, and its cash tier of as low as $499 a month runs through a savings card that requires commercial insurance and excludes government beneficiaries.

Does Medicare cover Zepbound for weight loss?

Through the Medicare GLP-1 Bridge, eligible Part D patients with a Zepbound prescription for weight management pay no more than $50 a month. The program runs from 1 July 2026 to 31 December 2027 and covers the KwikPen only. That spending is excluded from the $2,100 Part D out-of-pocket cap, so it does not move you toward catastrophic coverage.

Does Medicaid cover Zepbound in 2026?

In 13 states as of January 2026. California, Pennsylvania, New Hampshire and South Carolina dropped obesity GLP-1 coverage on 1 January 2026, so a state that covered it last year may not cover it now. Coverage for type 2 diabetes is far broader than coverage for obesity. Check your state’s current preferred drug list.

Is compounded tirzepatide cheaper than Zepbound?

Less than it used to be. Compounded tirzepatide runs roughly $199 to $399 a month at standard rates, and brand self-pay starts at $299, so the ranges overlap at low doses. At a $449 maintenance dose compounded is clearly cheaper. Compounded tirzepatide is not an FDA-approved product.

Can I use an HSA or FSA to pay for Zepbound?

Yes, with a prescription. Paying from an HSA or FSA does not change the sticker price, but it lowers your effective cost by your marginal tax rate. On a $449 dose that is real money, and it works on any of the routes described above, including LillyDirect self-pay.